An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...
This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...
This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...
This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...
Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...
